Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.

Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA.

Cancer Immunol Immunother. 2006 May;55(5):503-14. Epub 2005 Jul 20.

PMID:
16032400
2.

T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.

Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, Bargou RC.

J Immunol. 2003 Apr 15;170(8):4397-402.

3.

Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.

Klein SC, Boer LH, de Weger RA, de Gast GC, Bast EJ.

Scand J Immunol. 1997 Nov;46(5):452-8.

4.

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA.

Mol Immunol. 2007 Mar;44(8):1935-43. Epub 2006 Nov 2.

PMID:
17083975
5.

T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.

Gruen M, Bommert K, Bargou RC.

Cancer Immunol Immunother. 2004 Jul;53(7):625-32. Epub 2004 Feb 6.

PMID:
15175907
6.

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.

Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, Prang N, Bargou R, Suzich J, Baeuerle PA, Hofmeister R.

Cancer Immunol Immunother. 2007 Oct;56(10):1551-63. Epub 2007 Feb 20.

PMID:
17310380
7.

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.

Löffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, Dörken B, Bargou RC.

Leukemia. 2003 May;17(5):900-9.

PMID:
12750704
8.

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC.

Blood. 2000 Mar 15;95(6):2098-103.

9.

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA.

Int J Cancer. 2005 May 20;115(1):98-104.

10.

Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.

Kufer P, Mack M, Gruber R, Lutterbüse R, Zettl F, Riethmüller G.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):193-7.

PMID:
9435872
11.
12.

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.

Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA.

Mol Immunol. 2006 Mar;43(8):1129-43. Epub 2005 Sep 1.

PMID:
16139892
13.

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.

Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA.

Int J Cancer. 2002 Aug 20;100(6):690-7.

14.
15.
16.

Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.

Lefterova P, Märten A, Buttgereit P, Weineck S, Scheffold C, Huhn D, Schmidt-Wolf IG.

J Immunother. 2000 May-Jun;23(3):304-10.

PMID:
10838659
17.

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.

Hsu DH, Shi JD, Homola M, Rowell TJ, Moran J, Levitt D, Druilhet B, Chinn J, Bullock C, Klingbeil C.

Transplantation. 1999 Aug 27;68(4):545-54.

PMID:
10480415
18.
19.
20.

Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb.

Jacobs N, Greimers R, Mazzoni A, Trebak M, Schaaf-Lafontaine N, Boniver J, Moutschen MP.

Cancer Immunol Immunother. 1996 Jul;42(6):369-75.

Supplemental Content

Support Center